🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re delighted to welcome Andrew Beelen, MD, to Incyclix as our VP of Clinical Development. He brings a wealth of experience and expertise in #CDK inhibitor development and will play a pivotal role in progressing the clinical development of INX-315. incyclixbio.com/news_releases/…

We're pleased to welcome Emily O’Koren, our new senior manager for project development. Emily is a seasoned project manager with experience in preclinical and clinical programs, including multiple oncology studies. We’re thrilled to welcome her to our growing Incyclix team!

Join us to spread awareness of the vital need for more research and treatments to improve outcomes for patients with #metastaticbreastcancer. Learn more about the trial of our #CDK2 inhibitor in patients with metastatic cancer: incyclixbio.com/our-science/#o… #BreastCancerAwarenessMonth

#NationalMammographyDay is an important reminder that early detection is the best defense against #breastcancer. Mammograms can detect breast cancer before symptoms appear and increase chances of successful treatment. Remember to schedule your regular mammogram 📅

We’re presenting data from our Phase 1/2 clinical trial evaluating INX-315, our novel, potent and selective #CDK2 inhibitor, for the treatment of advanced and resistant #breastcancer at #SABCS24. Learn more: incyclixbio.com/news_releases/…

We’re thrilled to welcome Dr. Norman Sharpless, former NCI director and FDA commissioner, to our Board of Directors. Dr. Sharpless brings unparalleled oncology expertise and experience to our Board at this important point in our growth. Read more: incyclixbio.com/news_releases/…

We’re pleased to announce a clinical trial collaboration and supply agreement with Eli Lilly and Company for supply of its CDK4/6 inhibitor Verzenio® (abemaciclib) for use in combination with INX-315 and fulvestrant for treatment of HR+/HER2- #breastcancer. incyclixbio.com/news_releases/…

Attending the #SABCS24? Don’t miss the poster presentation sharing clinical data from our Phase 1/2 clinical trial of INX-315, our novel, potent and selective #CDK2 inhibitor, in advanced and resistant cancer. More details here: incyclixbio.com/news_releases/… #SABCS24

At SABCS, we presented interim clinical data demonstrating the safety, tolerability and antitumor activity of our #CDK2 inhibitor in advanced and resistant cancer. Read more: incyclixbio.com/news_releases/… View the poster presentation here: incyclixbio.com/publications/ #SABCS24

We’re pleased to welcome Thomas McNamara to the Incyclix team as our new senior director of business development. His years of experience in biopharma corporate and business development will be a vital asset as Incyclix continues to grow.

We’re thrilled to welcome Daniel Klem, our new senior manager of clinical operations, to the Incyclix team. He brings over 14 years of experience in clinical research to his new role where he will be responsible for driving the clinical development of INX-315.

We’re pleased that a publication highlighting research identifying biomarkers of response to our #CDK2 inhibitor, INX-315, and validating its potential to overcome resistance to CDK4/6 inhibitors in certain cancers was published in Nature Communications. incyclixbio.com/news_releases/…

Incyclix Bio is excited support the No Patient Left Behind’s mission to make innovative and transformational therapies affordable and accessible to patients that need them! Stay tuned for more important messages from biotech leaders. #NPLBCommunityQuest #NoPatientLeftBehind

Knowing the hormone receptor status of your #breastcancer helps determine the best treatment. Learn more about the types of hormone receptors in breast cancer cells and how they affect treatment resistance: cancer.org/cancer/types/b…

While cancer awareness, prevention and early detection can save lives, tackling advanced, treatment-resistant cancers requires bold, innovative science. We’re focused on targeting CDK2 to develop a new treatment option for patients who need it most. 🔬 incyclixbio.com

#NEWS: The U.S. FDA has granted Fast Track designation for INX-315, our investigational #CDK2 inhibitor, for the treatment of patients with CCNE1-amplified platinum-resistant/refractory #ovariancancer. incyclixbiostg.wpengine.com/news_releases/…

With no #ovariancancer early test or reliable screening, awareness is vital. We’re devoted to helping everyone #KnowOvarian for #WOCD2025 and with the INX-315 Fast Track designation, we're closer to advancing care for platinum-resistant ovarian cancer. ➡️ incyclixbio.com/patients/

CEO Patrick Roberts was featured among the biotech leaders contributing to the advancement of #breastcancer treatment in No Patient Left Behind's Breast Cancer #CommunityQuest video! Watch the full video and learn more here ⬇️ nopatientleftbehind.org/the-quest-to-c… #CancerSurvivorsMonth

Ovarian Cancer is the 8th leading cause of cancer-related deaths among women and treatment options for advanced cases are limited. We’re working to accelerate development of our #CDK2 inhibitor to bring hope to individuals with advanced #ovariancancer. incyclixbio.com

#NewPublication: Findings from a recent study showed knock down of #CDK2 or treatment w/ INX-315 in extreme non-responder (ENR) prostate cancer cell lines reduced cell viability and AR target genes, suggesting potential use in #prostatecancer. npj Journals: nature.com/articles/s4169…